Healthcare Industry News: Alzheimer's
News Release - November 6, 2006
Acumen Pharmaceuticals Names Dr. William F. Goure Chief Operating OfficerSOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Acumen Pharmaceuticals, a leading pre-clinical biotech company in the Alzheimer's research space, today announced that it has promoted Dr. William F. Goure to the post of Chief Operating Officer (COO). A veteran of more than 20 years in the discovery, development, registration, commercial development and commercialization of chemical and biotechnology products, Dr. Goure formerly served as vice president for Business Development at the company.
In his new role, Dr. Goure will be responsible for leading Acumen's organization operations and directing and coordinating activities to ensure achievement of corporate goals and objectives set by Chief Executive Officer, Chief Scientific Officer and Board of Directors.
"As we move closer to our goal of developing disease modifying therapeutics for Alzheimer's disease, we increasingly recognize the value of contributors like Bill Goure," said David Summa, president and CEO at Acumen. "His drive, high standards and focus on execution are real assets to our organization."
Prior to joining Acumen in 2004, Dr. Goure acted as Vice President for Commercial Development for Mendel Biotechnology, a San Francisco Bay area company working towards the discovery, development and commercialization of plant gene expression. At Mendel, Dr. Goure negotiated numerous technology collaboration and partnership agreements that generated more than $29 million dollars of near-term revenues. Dr. Goure also worked at Monsanto Company for 17 years with positions in discovery, product development, environmental sciences, and business development. Dr. Goure also commercialized Roundup Ready ® soybeans, canola and cotton globally.
Dr. Goure has a B.S. degree in chemistry from Fort Lewis College in Durango, Colorado and a Ph.D. degree in organic chemistry from Iowa State University. Prior to joining Monsanto, he was a Post-Doctoral Fellow at Colorado State University.
Acumen Pharmaceuticals Inc. (www.acumenpharm.com) is a venture-backed, pre-clinical biotech company focused on developing the first effective therapeutics and diagnostics for Alzheimer's disease and other memory-related disorders. Founded in 1996, Acumen owns or has licensed the critical patents underlying the ADDL mechanism now widely believed to cause Alzheimer's disease. In addition to ELISA-based diagnostic, Acumen has several therapeutic approaches to stop ADDL-related diseases. NeuroVentures LLC has made a seed investment in the company.
Source: Acumen Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.